Literature DB >> 22079255

Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Rebecca J Hermann1, Travis Van der Steen, Emilie E Vomhof-Dekrey, Sejaa Al-Badrani, Steve B Wanjara, Jarrett J Failing, Jodie S Haring, Glenn P Dorsam.   

Abstract

Vasoactive intestinal peptide receptor-1 signaling in lymphocytes has been shown to regulate chemotaxis, proliferation, apoptosis and differentiation. During T cell activation, VPAC1 mRNA is downregulated, but the effect on its protein levels is less clear. A small number of studies have reported measurement of human VPAC1 by flow cytometry, but murine VPAC1 reagents are unavailable. Therefore, we set out to generate a reliable and highly specific α-mouse VPAC1 polyclonal antibody for use with flow cytometry. After successfully generating a rabbit α-VPAC1 polyclonal antibody (α-mVPAC1 pAb), we characterized its cross-reactivity and showed that it does not recognize other family receptors (mouse VPAC2 and PAC1, and human VPAC1, VPAC2 and PAC1) by flow cytometry. Partial purification of the rabbit α-VPAC1 sera increased the specific-activity of the α-mVPAC1 pAb by 20-fold, and immunofluorescence microscopy (IF) confirmed a plasma membrane subcellular localization for mouse VPAC1 protein. To test the usefulness of this specific α-mVPAC1 pAb, we showed that primary, resting mouse T cells express detectable levels of VPAC1 protein, with little detectable signal from activated T cells, or CD19 B cells. These data support our previously published data showing a downregulation of VPAC1 mRNA during T cell activation. Collectively, we have established a well-characterized, and highly species specific α-mVPAC1 pAb for VPAC1 surface measurement by IF and flow cytometry.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079255      PMCID: PMC3273623          DOI: 10.1016/j.jim.2011.10.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  51 in total

1.  Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors.

Authors:  Kaleeckal G Harikumar; Maria M Morfis; Cayle S Lisenbee; Patrick M Sexton; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2005-10-21       Impact factor: 4.436

Review 2.  Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.

Authors:  I Langer; P Robberecht
Journal:  Biochem Soc Trans       Date:  2007-08       Impact factor: 5.407

3.  Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

Authors:  Mario Delgado; Gema Robledo; Blanca Rueda; Nieves Varela; Francisco O'Valle; Pedro Hernandez-Cortes; Marta Caro; Gisela Orozco; Elena Gonzalez-Rey; Javier Martin
Journal:  Arthritis Rheum       Date:  2008-04

4.  Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.

Authors:  Christelle Langlet; Ingrid Langer; Pascale Vertongen; Nathalie Gaspard; Jean-Marie Vanderwinden; Patrick Robberecht
Journal:  J Biol Chem       Date:  2005-06-02       Impact factor: 5.157

5.  PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

6.  PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.

Authors:  Kathleen Freson; Karen Peeters; Rita De Vos; Christine Wittevrongel; Chantal Thys; Marc F Hoylaerts; Jos Vermylen; Chris Van Geet
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

7.  TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells.

Authors:  Emilie E Vomhof-DeKrey; Rebecca J Hermann; Megan F Palmer; Keith D Benton; Ashley R Sandy; Sheri T Dorsam; Glenn Paul Dorsam
Journal:  Brain Behav Immun       Date:  2008-06-04       Impact factor: 7.217

8.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.

Authors:  Emilie Ceraudo; Samuel Murail; Yossan-Var Tan; Jean-Jacques Lacapère; Jean-Michel Neumann; Alain Couvineau; Marc Laburthe
Journal:  Mol Endocrinol       Date:  2007-09-20

9.  Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.

Authors:  Marzia Barberi; Barbara Muciaccia; Maria Beatrice Morelli; Mario Stefanini; Sandra Cecconi; Rita Canipari
Journal:  Reproduction       Date:  2007-08       Impact factor: 3.906

10.  Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

Authors:  Emilie E Vomhof-DeKrey; Glenn Paul Dorsam
Journal:  Brain Behav Immun       Date:  2008-06-13       Impact factor: 7.217

View more
  2 in total

1.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

2.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.